Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic.

ABSTRACT:

Background and objectives

Cebranopadol is a novel first-in-class analgesic acting as a nociceptin/orphanin FQ peptide and opioid peptide receptor agonist with central analgesic activity. It is currently in clinical development for the treatment of chronic pain conditions. This trial focuses on the clinical pharmacokinetic (PK) properties of cebranopadol after oral single- and multiple-dose administration.

Methods

The basic PK properties of cebranopadol were assessed by means of noncompartmental methods in six phase I clinical trials in healthy subjects and patients. A population PK analysis included two further phase I and six phase II clinical trials.

Results

After oral administration of the immediate-release (IR) formulation, cebranopadol is characterized by a late

SUBMITTER: Kleideiter E 

PROVIDER: S-EPMC5766727 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature